Search Results - "Muñoz Mateu, Montserrat"

Successful Integration of EN/ISO 13606-Standardized Extracts From a Patient Mobile App Into an Electronic Health Record: Description of a Methodology by Frid, Santiago, Fuentes Expósito, Maria Angeles, Grau-Corral, Inmaculada, Amat-Fernandez, Clara, Muñoz Mateu, Montserrat, Pastor Duran, Xavier, Lozano-Rubí, Raimundo

“…There is an increasing need to integrate patient-generated health data (PGHD) into health information systems (HISs). The use of health information standards…”
Get full text

Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients by Pascual, Javier, Gil-Gil, Miguel, Proszek, Paula, Zielinski, Christoph, Reay, Alistair, Ruiz-Borrego, Manuel, Cutts, Rosalind, Ciruelos Gil, Eva M, Feber, Andrew, Muñoz-Mateu, Montserrat, Swift, Claire, Bermejo, Begoña, Herranz, Jesus, Margeli Vila, Mireia, Antón, Antonio, Kahan, Zsuzsanna, Csöszi, Tibor, Liu, Yuan, Fernandez Garcia, Daniel, Garcia-Murillas, Isaac, Hubank, Michael, Turner, Nicholas C, Martín, Miguel

“…Prognostic and predictive biomarkers to CDK4/6 inhibitors are lacking. Circulating tumour DNA (ctDNA) can be used to profile these patients and dynamic changes…”
Get full text

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer by Guerrero-Zotano, Ángel, Belli, Stefania, Zielinski, Christoph, Gil-Gil, Miguel, Fernandez-Serra, Antonio, Ruiz-Borrego, Manuel, Ciruelos Gil, Eva Maria, Pascual, Javier, Muñoz-Mateu, Montserrat, Bermejo, Begoña, Margeli Vila, Mireia, Antón, Antonio, Murillo, Laura, Nissenbaum, Bella, Liu, Yuan, Herranz, Jesús, Fernández-García, Daniel, Caballero, Rosalía, López-Guerrero, José Antonio, Bianco, Roberto, Formisano, Luigi, Turner, Nicholas, Martín, Miguel

“…In hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly to cyclin-dependent kinase…”
Get full text

Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial) by Mueller, Volkmar, Wardley, Andrew, Paplomata, Elisavet, Hamilton, Erika, Zelnak, Amelia, Fehrenbacher, Louis, Jakobsen, Erik, Curtit, Elsa, Boyle, Frances, Harder Brix, Eva, Brenner, Andrew, Crouzet, Laurence, Ferrario, Cristiano, Muñoz-Mateu, Montserrat, Arkenau, Hendrik-Tobias, Iqbal, Nayyer, Aithal, Sramila, Block, Margaret, Cold, Soeren, Cancel, Mathilde, Hahn, Olwen, Poosarla, Teja, Stringer-Reasor, Erica, Colleoni, Marco, Cameron, David, Curigliano, Giuseppe, Siadak, Muriel, DeBusk, Kendra, Ramos, Jorge, Feng, Wentao, Gelmon, Karen

“…In HER2CLIMB, tucatinib significantly improved progression-free and overall survival in patients with human epidermal growth factor receptor 2–positive (HER2+)…”
Get full text

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study by Martín, Miguel, Ruiz Simón, Amparo, Ruiz Borrego, Manuel, Ribelles, Nuria, Rodríguez-Lescure, Álvaro, Muñoz-Mateu, Montserrat, González, Sonia, Margelí Vila, Mireia, Barnadas, Agustí, Ramos, Manuel, Del Barco Berron, Sonia, Jara, Carlos, Calvo, Lourdes, Martínez-Jáñez, Noelia, Mendiola Fernández, César, Rodríguez, César A, Martínez de Dueñas, Eduardo, Andrés, Raquel, Plazaola, Arrate, de la Haba-Rodríguez, Juan, López-Vega, Jose Manuel, Adrover, Encarna, Ballesteros, Ana Isabel, Santaballa, Ana, Sánchez-Rovira, Pedro, Baena-Cañada, José M, Casas, Maribel, del Carmen Cámara, María, Carrasco, Eva Maria, Lluch, Ana

“…Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a…”
Get full text

Mapping the Evidence on the Impact of mHealth Interventions on Patient-Reported Outcomes in Patients With Breast Cancer: A Systematic Review by Frid, Santiago, Amat-Fernández, Clara, Fuentes-Expósito, María Ángeles, Muñoz-Mateu, Montserrat, Valachis, Antonis, Sisó-Almirall, Antoni, Grau-Corral, Immaculada

“…To comprehensively synthesize the existing evidence concerning mHealth interventions for patients with breast cancer (BC). On July 30, 2023, we searched…”
Get more information

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study by MARTIN, Miguel, RUIZ, Amparo, MUNOZ-MATEU, Montserrat, DORCA RIBUGENT, Joan, LOPEZ-VEGA, José Manuel, JARA, Carlos, ESPINOSA, Enrique, MENDIOLA FERNANDEZ, César, ANDRES, Raquel, RIBELLES, Nuria, PLAZAOLA, Arrate, SANCHEZ-ROVIRA, Pedro, RUIZ BORREGO, Manuel, SALVADOR BOFILL, Javier, CRESPO, Carmen, CARABANTES, Francisco J, SERVITJA, Sonia, IGNACIO CHACON, José, RODRIGUEZ, César A, HERNANDO, Blanca, ALVAREZ, Isabel, CARRASCO, Eva, LLUCH, Ana, BARNADAS, Agustí, GONZALEZ, Sonia, CALVO, Lourdes, MARGELI VILA, Mireia, ANTON, Antonio, RODRIGUEZ-LESCURE, Alvaro, SEGUI-PALMER, Miguel Angel

“…Adding taxanes to anthracycline-based adjuvant therapy improves survival outcomes of patients with node-positive breast cancer (BC). Currently, however, most…”
Get full text

SEOM clinical guidelines for the treatment of early breast cancer by del Barco Berrón, Sonia, Ciruelos Gil, Eva, Tusquets Trías de Bes, Ignacio, Muñoz Mateu, Montserrat, Sánchez Rovira, Pedro, Rodríguez Lescure, Álvaro, Isla Casado, Dolores

“…The incidence is increasing due to mammographic screening and an ageing population. In some countries the mortality rate has decreased especially in middleaged…”
Get full text

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study by de Dueñas, Eduardo Martínez, Hernández, Ana Lluch, Zotano, Ángel Guerrero, Carrión, Ramón María Pérez, López-Muñiz, José Ignacio Chacón, Novoa, Silvia Antolín, Rodríguez, Ángela López, Fidalgo, José Alejandro Pérez, Lozano, Jaime Ferrer, Gasión, Octavio Burgués, Carrascal, Eva Carrasco, Capilla, Andrés Hernando, López-Barajas, Isabel Blancas, Mateu, Montserrat Muñoz, de Ceballos Reyna, María Helena López, Ferrando, Amparo Oltra, Jañez, Noelia Martínez, Ballerini, Vicente Carañana, Torres, Antonio Antón, Catalán, Gustavo, Sáenz, José Ángel García, Menjón, Salomón, González-Angulo, Ana María

“…The objective of this study was to determine the conversion rate of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and progesterone…”
Get full text

Bevacizumab plus Letrozol (LEA clinical trial phase III). Using hypertension for finding biomarkers of efficacy by de la Haba-Rodriguez, Juan, Morales, Serafin, Guerrero, Angel, Martinez, Noelia, Martinez Peinado, Antonio, Anton, Antonio, Munoz-Mateu, Montserrat, Garcia Saenz, Jose Angel, Ramos Vazquez, Manuel, Gil Gil, Miguel J., Margeli, Mireia, Servitja, Sonia, Bermejo, Begona, Jurado, Josefina Cruz, Aranda, Enrique, Casas, Maribel, Rodríguez-Martín, César, Carrasco, Eva Maria, Caballero, Rosalia, Martin, Miguel

“…Abstract only…”
Get full text

Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel by Rojo, Federico, Lluch, Ana, Ruiz, Amparo, Ruiz-Borrego, Manuel, Barnadas, Agusti, Calvo, Lourdes, Gonzalez, Sonia, Margeli, Mireia, Rodriguez-Lescure, Alvaro, Anton, Antonio, Seguí, Miguel Angel, Munoz-Mateu, Montserrat, Dorca, Joan, Lopez-Vega, Jose Manuel, Jara-Sanchez, Carlos, Martin, Nuria, Casas, Maribel, Carrasco, Eva Maria, Caballero, Rosalia, Martin, Miguel

“…Abstract only…”
Get full text

Breast cancer risk among women following lifestyle recommendations: A case-control study in Spain by Pollán, Marina, Castello, Adela, Ruiz, Amparo, Casas, Ana, Baena-Cañada, Jose Manuel, Lope, Virginia, Antolín, Silvia, Ramos Vazquez, Manuel, Munoz-Mateu, Montserrat, Lluch, Ana, De Juan, Ana, Jara-Sanchez, Carlos, Jimeno, M. Angeles, Rosado, Petra, Diaz Pena, Elena, Guillem, Vicente, Carrasco, Eva Maria, Perez-Gomez, Beatriz, Vioque, Jesus, Martin, Miguel

“…Abstract only…”
Get full text

Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): Efficacy analysis of the GEICAM/2003-10 trial by Bermejo, Begoña, Ruiz, Amparo, Ruiz Borrego, Manuel, Ribelles, Nuria, Rodriguez-Lescure, Alvaro, Munoz-Mateu, Montserrat, Gonzalez, Sonia, Margeli, Mireia, Barnadas, Agust, Ramos Vazquez, Manuel, del Barco, Sonia, Calvo, Lourdes, Mendiola, Cesar, Crespo, Carmen, Rodriguez, Cesar Augusto, Martinez, Eduardo, Casas, Maria Isabel, Camara, M Carmen, Carrasco, Eva Maria, Martin, Miguel

“…Abstract only 1027 Background: X is an active drug in metastatic breast cancer. GEICAM/2003-10 is an adjuvant trial investigating the integration of…”
Get full text

Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial by Martin, Miguel, Lluch, Ana, Ruiz, Amparo, Ruiz Borrego, Manuel, Barnadas, Agust, Gonzalez, Sonia, Calvo, Lourdes, Margeli Vila, Mireia, Anton, Antonio, Rodriguez-Lescure, Alvaro, Seguí-Palmer, Miguel Angel, Munoz-Mateu, Montserrat, Dorca Ribugent, Joan, Lopez-Vega, Jose Manuel, Mendiola Fernandez, Cesar, Andres, Raquel, Plazaola, Arrate, Rodriguez, Cesar, Casas, Maria Isabel, Carrasco, Eva Maria

“…Abstract only 1001 Background: Adjuvant weekly paclitaxel (wP) sequential to anthracyclines improves the outcome of operable node-positive BC patients (pts)…”
Get full text